PD-L1 expression in inflammatory myofibroblastic tumors

Cottrell, Tricia R.; Duong, Anh T; Gocke, Christopher D.; Xu, Huimin; Ogurtsova, Aleksandra; Taube, Janis M.; Belchis, Deborah A.

doi:10.1038/s41379-018-0034-6

Cited by 17 publications

(10 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Other therapeutic strategies are being developed. For example, PD-L1 expression was noted in 80% of recurrent or metastatic tumors, and 88% of ALK -negative IMTs [ 61 ]. Due to PD-L1 expression in EIMS, immune checkpoint blockade could represent an alternative anti-EIMS therapy [ 62 ].…”

Section: Current Treatmentsmentioning

confidence: 99%

Inflammatory Myofibroblastic Tumour: State of the Art

Gros

Tos

Jones

et al. 2022

Cancers

View full text Add to dashboard Cite

An inflammatory myofibroblastic tumor (IMT) is a neoplasm composed of myofibroblastic and fibroblastic spindle cells accompanied by inflammatory cells, including lymphocytes and eosinophils. It is an ultra-rare tumor, the optimal management of which remains to be defined. Surgery is the treatment of choice for localized tumors. The treatment of advanced disease is not precisely defined. Chemotherapy regimens result in an overall response rate of approximately 50% based on retrospective data. The latest pathophysiological data highlight the role played by tyrosine kinase fusion genes in IMT proliferation. Anaplast lymphoma kinase (ALK) oncogenic activation mechanisms have been characterized in approximately 80% of IMTs. In this context, data regarding targeted therapies are most important. The aims of this article are to review the latest published data on the use of systematic therapy, particularly the use of molecular targeted therapy, and to publish an additional case of an IMT with Ran-binding protein 2 (RANPB2)-ALK fusion showing a long response to a tyrosine kinase inhibitor.

show abstract

Section: Current Treatmentsmentioning

confidence: 99%

Inflammatory Myofibroblastic Tumour: State of the Art

Gros

Tos

Jones

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…Other kinase fusions in addition to ALK were identified in IMT, which were targeted with tyrosine kinase inhibitors, through the next-generation sequencing- (NGS-) based genomic assay [ 16 ]. Latest studies showed that IMTs expressed constitutive and adaptive PD-L1 frequently, especially in ALK-negative tumors, suggesting new therapeutic targets with anti-PD1/PDL1 therapy, which is popular in many other types of tumors [ 17 , 18 ]. The positive rate of PD-L1 in our study was comparable to that of previous study, so anti-PD1/PDL1 therapy may be used for IMTs of paranasal sinus and nasopharynx.…”

Section: Discussionmentioning

confidence: 99%

Inflammatory Myofibroblastic Tumors in Paranasal Sinus and Nasopharynx: A Clinical Retrospective Study of 13 Cases

Zhu

Zha

Wang

et al. 2018

BioMed Research International

View full text Add to dashboard Cite

Background Inflammatory myofibroblastic tumor (IMT), as a mesenchymal tumor, is common in the lung and abdomen but rare in the paranasal sinus and nasopharynx. Objective This study aimed to summarize the clinical characteristics of IMT in the paranasal sinus and nasopharynx and analyze the relationship between the treatment and the overall survival (OS). Method The clinical features, treatment, and follow-up data of patients diagnosed with IMT of the paranasal sinus or nasopharynx from 2006 to 2017 were retrospectively analyzed, and the previous literature was reviewed. Results IMT often presents as an ill-defined soft-tissue mass with bone destruction and invasion of surrounding structures. The treatment methods used in this study were different combinations of surgery, prednisone, radiotherapy, and chemotherapy or observation alone. Three of the 13 patients were lost and the follow-up time of the remaining 10 cases ranged from 2 to 87 months (median, 39 months). Two patients died of the disease; the other eight patients were stable. The 5-year survival rate was 72%. Among the four methods of treatment, only treatment with prednisone was significantly correlated with better OS (P = 0.046). Conclusions IMT is an intermediate tumor that often mimics malignancy. We are not sure if IMTs in the nasal cavity are more aggressive because of the biology or if the location and local therapy in the head region is more complicated. Radiologic findings help know the extent of the lesion. For unresectable nasal IMT, combined therapy with glucocorticoids, chemotherapy, and radiotherapy is sometimes a better choice. Glucocorticoids are especially recommended as a basic part of the integrated therapy. However, the standard treatment needs further research.

show abstract

“…To get a better idea of PD-L1 expression pattern, the percentage of tumor and intratumoral immune cells were evaluated separately, and further scored as 1 + (1% to 10%), 2 + (11% to 30%) and 3 + (> 30%) based on percentages of positive cells. Adaptive PD-L1 expression pattern was defined as PD-L1 positivity seen in both tumor and infiltrating immune cells 32 .…”

Section: Methodsmentioning

confidence: 99%

PD-L1 expression in angiomatoid fibrous histiocytoma

Byers

Yin

Rytting

et al. 2021

Sci Rep

View full text Add to dashboard Cite

Angiomatoid fibrous histiocytoma (AFH) is a rare tumor of intermediate malignancy. Treatment options for unresectable and/or metastatic tumors are very limited. Immunotherapy with PD-1/PD-L1 inhibitors may be worth exploring. The aim of this study was to evaluate the expression of PD-L1 in AFHs. PD-L1 expression was assessed on 36 AFHs from 36 pediatric patients by immunohistochemical staining of PD-L1 (clone 22C3). Positivity was defined as membranous expression in ≥ 1% of either tumor or immune cells. The correlations between PD-L1 expression and clinicopathologic features were assessed. Two patients had lymph node metastasis. All patients underwent surgical resection; three of them also had systemic chemotherapy. Three patients had recurrence after initial resection; all patients were alive with a median follow-up of 2.5 years. Overall, twenty-two (61%) tumors were positively stained for PD-L1 and positivity was seen on both tumor and immune cells in eighteen of the 22 tumors. A positive correlation was found between tumor cell PD-L1 expression and CD8+ T-cell infiltration. There were no statistically significant differences between the status of PD-L1 expression and the clinicopathological features assessed. PD-L1 expression was identified in 61% of AFHs with a predominantly adaptive pattern. Our findings provide a rationale for future studies evaluating the potential of checkpoint immunotherapy for patients with unresectable and/or metastatic tumor.

show abstract

PD-L1 expression in inflammatory myofibroblastic tumors

Cited by 17 publications

References 31 publications

Inflammatory Myofibroblastic Tumour: State of the Art

Inflammatory Myofibroblastic Tumour: State of the Art

Inflammatory Myofibroblastic Tumors in Paranasal Sinus and Nasopharynx: A Clinical Retrospective Study of 13 Cases

PD-L1 expression in angiomatoid fibrous histiocytoma

Contact Info

Product

Resources

About